Company intelligence / Profile preview

Galenic Strategies

Windsor, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Galenic Strategies is a pharmaceutical development consultancy and virtual biotech firm led by Dr. Gary T. Elliott. The firm provides high-level strategic and formulation guidance for the transition of novel drug candidates from preclinical stages to clinical trials. It is specifically recognized for its development work on Gamitrinib, a first-in-class mitochondrial-targeted Hsp90 inhibitor in Phase 1 for advanced cancers, and its contribution to the development of HBI-3000, a multi-ion channel blocker in Phase 2 for atrial fibrillation.

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

HUYABIO InternationalThe Wistar InstituteNational Cancer Institute (NCI)Fox Chase Cancer Center

Beyond the preview

Go deeper on Galenic Strategies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galenic Strategies.

Explore the full profile